Renal cell carcinoma. Guidelines for diagnosis and treatment

Urologia Internationalis

Volumn 63, Issue 1, 1999, Pages 6-9

  Miller, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Diagnostic standards; Immunotherapy; Renal cell carcinoma; Therapeutic standards; Tumor nephrectomy

Indexed keywords

CANCER DIAGNOSIS; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; TUMOR VOLUME;

EID: 0032746486     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030411     Document Type: Short Survey

References (34)

1. Atzpodien J, Hänninen LE, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T, et al: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995;13:497-501.
2. Bassil B, Dosoretz DE, Prout GR Jr: Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 1985;134:450-454.
3. Branscheid D, Krysa S, Soelben E, Bülzebruck H, Probst G, Vogt-Moykopf I: Chirurgische Therapie von Lungenmetastasen beim Nierenzellkarzinom - Diagnostik. Strategie, Ergebnisse. Akt Urol 1992;23:106-110.
4. Cidlinsky K, Engelhard K, Helmbrecht J: Die Problematik der präoperativen Dignitätseinstellung bei atypischen Nierentumoren. Röntgenpraxis 1992;45:8-15.
5. Ferucci J, Wittenberg TJ, Margolecs MN, Carrey RW: Malignant seeding of the tract after thin needle aspiration biopsy. Radiology 1979;130: 345-346.
6. Funke I, Späth-Schwalbe E, Stohlmann G, Prümmer O, Gallati H, Schrezenmeier H, Porszolt F: Subcutaneous IL-2 and low-dose IFN-α2a in the treatment of unselected patients with advanced renal cell cancer. Onkologie 1994;17: 263-269.
7. Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creckmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL: Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. J Clin Oncol 1996;14: 2234-2241.
8. Golimbu J, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P: Renal cell carcinoma: Survival and prognostic factors. Urology 1986;27:291-301.
9. Hänninen LE, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
10. Hofmockel G, Theiss M, Gruss A, Langer W, Frohmüller H: Biochemotherapie mit Interleukin-2, Interferon-α und 5-Fluorouracil für die Behandlung von Patienten mit metastasiertem Nierenzellkarzinom. Urologe [A] 1997;35:45-49.
11. Johnson CD, Dunnick NR, Cohan RH, Illescas FF: Renal adenocarcinoma: CT staging of 100 tumors. Am J Roentgenol 1987;148:59-63.
12. Johnson DE, Kaesler KE, Samuels ML: Is nephrectomy justified in patients with metastatic renal carcinoma? J Urol 1975;114:27-29.
13. Katz SE, Shapira HE: Spontaneous regression of genitourinary cancer: An update. J Urol 1982; 128:1-4.
14. Katz DL, Zheng T, Holford TR, Flannery J: Time trends in the incidence of renal carcinoma: Analysis of Connecticut Tumor Registry data, 1935-1989. Int J Cancer 1994;58:57-63.
15. Kjaer M: The treatment and prognosis of patients with renal adcnocarcinoma with solitary metastasis. 10-year survival results. Int J Radiat Oncol Biol Phys 1987;13:619-621.
16. Kozak W, Holtl W, Pummer K, Maier U, Jeschke K, Bucher A: Adrenalectomy - still a must in radical renal surgery? Br J Urol 1996;77:27-31.
17. Kriegmair M, Oberneder R, Hofstetter A: Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995;45:758-762.
18. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995;76:824-832.
19. Maldazys JD, DeKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol 1986;136: 376.
20. Marshall ME, Wolf M, Crawford ED, Thompson IM, Flanigan R, Balcerzak SP, Meyers FJ: Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: A Southwest Oncology Group study. Cancer Biother 1995;10:205-209.
21. Moll V, Becht E, Ziegler M: Kidney preserving surgery in renal cell tumors: Indications, technique and results in 152 patients. J Urol 1993; 150:319-323.
22. Morgan WR, Zineke H: Progression and survival after renal-conserving surgery for renal cell carcinoma: Experience in 104 patients and extended follow-up. J Urol 1990;144:852-858.
23. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-1957.
24. Newhouse JH: The radiologie evaluation of the patient with renal cancer. Urol Clin N Am 1993;20:231-246.
25. Palko A, Kulin E, Grexa E, Hertelendy A: Renal cell carcinoma: Value of imaging examinations in diagnosing and staging. Fortschr Röntg Strahl 1990;153:585-590.
26. Peters PC, Brown GL: The role of lymphadenectomy in the management of renal cell carcinoma. Urol Clin North Am 1980;7:705-709.
27. Pfeiffer D: Nierenzellkarzinome: Die farbkodierte Dopplersonographie in der Diagnostik venöser Tumorthromben. Akt Urol 1994;25:1-7.
28. Pizzocaro G, Piva L, DiFronzo G, Giongo A, Cozzoli A, Dormia E, Minervini S, Zanollo A, Fontanella U, Longo G, Maggioni A: Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987; 138:1379-1381.
29. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119-1123.
30. Steinbach F, Stöckle M, Hohenfellner R: Current controversies in nephron-sparing surgery for renal cell carcinoma. World J Urol 1995;13: 163-165.
31. Steinbach F, Stöckle M, Müller SC, Thüroff JW, Melchior SW, Stein R, Hohenfellner R: Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J Urol 1992; 148:24-30.
32. Winter P, Miersch WD, Vogel J, Jaeger N: On the necessity of adrenal extirpation combined with radical nephrectomy. J Urol 1990;144:842-843.
33. Witte RS, Leong T, Ernstoff MS, Krigel RL, Oken MM, Harris J, Tormey DC, Trump DL: A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma. Invest New Drugs 1995;13:241-247.
34. Yagoda A: Chemotherapy of renal cell carcinoma: 1983-1989, Semin Urol 1989;7:199-206.